MDMA and psilocybin

Authorised psychiatrists can prescribe products containing 3,4‑methylenedioxy‑methamphetamine (MDMA) or psilocybin for specific mental health conditions from 1 July 2023. 

MDMA may be used for the treatment of post-traumatic stress disorder. 

Psilocybin may be used for treatment-resistant depression. 

Prescribe MDMA or psilocybin

To prescribe products containing MDMA or psilocybin, you must be a registered psychiatrist. You must have completed a Fellowship with the Royal Australian and New Zealand College of Psychiatrists (RANZCP).

You must also be an Authorised Prescriber for each product you want to prescribe.

If authorised, you can prescribe:

• MDMA for post-traumatic stress disorder (PTSD)
• psilocybin for treatment-resistant depression (TRD)

Before you apply to become an Authorised Prescriber, consider the treatment options included in the Australian Register of Therapeutic Goods.

Become an Authorised Prescriber

To become an Authorised Prescriber of products containing MDMA or psilocybin, you will need human research ethics committee (HREC) approval.

When you apply, use the standard pathway. You can't use the established history of use pathway for MDMA or psilocybin.

Read how to become an Authorised Prescriber.